Kornimate/medical-research-clean huggingface dataset:
physiological and psycho-social variables of people with a spinal cord injury participating in competitive rugby in wheelchairs

Conditions: Wheelchair Rugby Players With Tetraplegia

Summary: people with spinal cord injury with tetraplegia suffer from respiratory problem due to weakness of the muscles and because the autonomic system dysfunction. exercise is one way of preserving and improving physical fitness and directly and indirectly reduce risk factors such as insulin resistance, weight loss and low values of hdl. subjects with spinal cord injury with tetraplegia have limited options for exercise: table tennis, gym, pool and more. because of the nature of the injury which includes the sympathetic failure, they can not easily get the desired pulse to improve physical fitness. wheelchair rugby in canada was developed specifically for people with tetraplegia who could not participate in wheelchair basketball. the game combines short, quick races with different aerobic capabilities. previous studies have shown that participants in wheelchair rugby improve anaerobic power, oxygen consumption, physical fitness and daily functioning. wheelchair rugby improves self-confidence and as a result it affects other areas of life. another study examined sense of self-efficacy, saw improvement in this index for rugby players in a wheelchair at high levels. in the present study the investigators aim to examine whether regular participation in wheelchair rugby for a season has more impact than other routine exercise (table tennis, gym, swimming).


Eligibility criteria:
inclusion criteria: * subjects with tetraplegia who play wheelchair rugby exclusion criteria: * suffering from a medical condition that prevents from performing the tests required by the study protocol.
study evaluating long-term safety and efficacy of lacosamide in subjects with painful distal diabetic neuropathy.

Conditions: Painful Diabetic Neuropathy

Summary: sp746 (nct00546351) is a multi-center, open-label, follow-on trial. the purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as spm 927) in subjects with painful distal diabetic neuropathy.


Eligibility criteria:
inclusion criteria: * subjects who completed study sp743 (nct00238524) or sp874 (nct00350103) and, in the investigator's opinion, might benefit from long-term administration of sp746 (nct00546351). exception: subjects who prematurely discontinued * sp743 (nct00238524) or sp874 (nct00350103) due to lack of efficacy or due to intolerability to trial medication (after visit 5but prior to entering the maintenance phase) may be eligible to participate in sp746 (nct00546351), after consultation with the medical monitor exclusion criteria: * subject has clinically relevant ecg abnormalities, or a qtc interval ≥500 ms, and/or a qtc interval increase of ≥60 ms from the mean pre-dose qtc value at visit 2 of sp743 (nct00238524) or sp874 (nct00350103) * subject has aspartate aminotransferase (ast) and/or alanine aminotransferase (alt) ≥3 times the upper limit of the normal range (uln) with total bilirubin ≥2 times uln or transaminases (ast and/or alt) ≥5 times uln * subject has a clinically relevant medical condition that, in the opinion of the investigator, jeopardizes or compromises the subject's ability to participate in this trial * subject is a pregnant or nursing female, or is of childbearing potential and is not surgically sterile, 2 years postmenopausal, or does not practice 2 combined methods of contraception

Keywords: lacosamide
a study of abt-751 in patients with non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of the study is to determine if abt-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. patients will receive abt-751 by mouth daily for 21 days. patients will be off drug for 7 days before starting the next cycle of drug.


Eligibility criteria:
inclusion criteria * stage iiib or iv non-small cell lung cancer. * recurrent tumor following treatment with paclitaxel or docetaxel. * able to tolerate normal activities of daily living. * adequate bone marrow, kidney and liver function. exclusion criteria * pregnant or breast feeding. * anti-tumor therapy within 4 weeks of the start of abt-751 administration. * cns metastasis.
value of ace index (albumin, crp and endoscopy) in predicting intra venous steroid response in acute severe ulcerative colitis in assiut university hospitals

Conditions: Early Detection of Complication of Ulcerative Colitis

Summary: 1. determine if the ace index can predict resoponse to i v steroid in acute severe ulcerative colitis 2. identify on admission a high-risk population who may beneft from earlier second line medical treatment or surgical intervention. ( steroid non responder groups )

ulcerative colitis is characterized by mucosal inflammation initiating in the rectum and extending proximally in the colon in a continuous fashion. in patients with acute severe colitis, prompt hospital admission is required, a multidisciplinary approach is fundamental, and contacting a colorectal surgeon at the moment of admission is recommended. sometimes, emergency surgery might be required early on in case of toxic megacolon, perforation or massive bleeding. although treatment initiation should not be postponed in severe cases, excluding differential diagnoses, including c. difficile infection, is crucial. a limited flexible sigmoidoscopy without bowel preparation should be performed to assess disease severity .(1) aggressive medical therapy, starting with intravenous corticosteroids. intravenous \[iv\] steroids remain the frst-line medical therapy for patients admitted with acute severe uc \[asuc\], as defned by truelove and witts criteria,)(2) almost one-third of patients, however, may not respond to iv steroids and go on to require second-line medical therapies \[primarily inﬂiximab or ciclosporin\] or a colectomy . a signifcant body of research in recent years has focused on predicting outcome in patients with asuc treated with iv steroids; ,(3) in 2022 the novel ace was reported \[albumin, crp, and endoscopy\] index in acute colitis, which used biochemical and endoscopic parameters to predict steroid non-response on admission (albumin ≤ 30g/l \[0 or 1\] + c-reactive protein \[crp\] ≥ 50 mg/l \[0 or 1\] + endoscopically severe according to physician's global assessment component of the mayo score \[0 or 1\]), we can identify a high-risk subset of patients for targeted counselling and early administration of second-line therapy; this is particularly crucial as treatment delays are associated with increased mortality.

Eligibility criteria:
inclusion criteria: - adult patients (≥18 years) known ulcerative colitis presented with activity . 2- newly diagnosed ulcerative colitis exclusion criteria: * 1) patient presented with cmv colitis 2) clostridium difficile infection 3) elective admission
pharmacokinetic study of rosuvastatin and lopinavir/ritonavir in hiv patients

Conditions: HIV Infections; Hyperlipidemia

Summary: open-label, multiple dose, single-group, 12 week trial in hiv-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.

to determine the effect of rosuvastatin on plasma lipids, lipoproteins, and endothelial function in hiv-infected patients on stable lopinavir/ritonavir therapy and to evaluate the safety of combined use of rosuvastatin and lopinavir/ritonavir. also to determine the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin compared to historical controls an to determine the effect of rosuvastatin on the pk of lopinavir/ritonavir compared to historical controls and by intrapatient comparison.

Eligibility criteria:
inclusion criteria: * use of lopinavir 400mg/ritonavir 100mg bid \> 3months * hiv-1 rna \<400cop/ml * fasting total cholesterol \> 6.2mmol/l exclusion criteria: * history of sensitivity/idiosyncrasy to the drug or compounds used * history or current condition that might interfere with absorption,distribution metabolism or excretion * pregnant or breast-feeding * serum transaminase levels \>3 times upper limit of normal, creatinine clearance \<60ml/min * fasting plasma triglycerides level \>8.0 mmol/l * history of statin-related rhabdomyolysis or inheritable muscle diseases in family history * clinical symptoms of myopathy or abnormal ck level * change in antiretroviral medication within the 3 months immediately preceding first dose of rosuvastatin * use of any statin or fibrate within 6 weeks immediately preceding first dose of rosuvastatin * concomitant use of medications that interfere with rosuvastatin or lopinavir pharmacokinetics * active hepatobiliary or hepatic disease * hypothyroidism * alcohol abuse * japanese or chinese patients

Keywords: hiv
management of antifungal drug in invasive aspergillosis：a real-word study

Conditions: Invasive Aspergillosis

Summary: to assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.

to assessed the current situation and outcome of critically ill patients with invasive aspergillus infection.

Eligibility criteria:
inclusion criteria: * age\>18 year-old * diagosed as invasive aspergillus infection exclusion criteria: * pregnant

Keywords: invasive aspergillus infection
effect of glycopyrronium in combination with tropisetron in anti-postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: to compare the anti-nausea and vomiting effect between glycopyrronium in combination with tropisetron and normal saline in combination with tropisetron for patients receiving elective surgery under general anesthesia. based on this study the investigators intend to explore the feasibility of using glycopyrronium as adjuvant drug to prevent postoperative nausea and vomiting.


Eligibility criteria:
inclusion criteria: * non-cardiac surgery * american society of anesthesiologists classification i-iii * receive general anesthesia * voluntarily receive postoperative intravenous controlled analgesia exclusion criteria: * puerpera or lactation women * allergy or existing contraindication to glycopyrronium and tropisetron * participate in other clinical drug trials within three months * can not follow with the study procedure
comparison of the efficacy of ticagrelor combined with asa to asa alone in patients with stroke

Conditions: Cerebrovascular Accident; Cerebrovascular Accident, Acute

Summary: cerebrovascular disease is the main cause of death and severe long-term disability worldwide. antiplatelet drugs are the main drugs for ischemic stroke and tia. cyclooxygenase inhibitor acetylsalicylic acid (asa) has always been the most widely studied antiplatelet therapy. the studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with ais or tia. the results showed that the number of patients with endpoint events in ticagrelor group was less than that in asa group, however, it has not been proved that ticagrelor monotherapy is better than asa. the purpose of this study is to prove that ticagrelor is better than asa.

cerebrovascular disease is the main cause of death and severe long-term disability worldwide. antiplatelet drugs are the main drugs for ischemic stroke and tia. cyclooxygenase inhibitor acetylsalicylic acid (asa) has always been the most widely studied antiplatelet therapy. the studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with ais or tia. the results showed that the number of patients with endpoint events in ticagrelor group was less than that in asa group, however, it has not been proved that ticagrelor monotherapy is better than asa. the purpose of this study is to prove that ticagrelor is better than asa. the study will be designed as a randomized, double-blind, placebo-controlled, parallel grouping study and conducted in multiple centers to ensure the representation of multiple countries, races and races, so as to ensure that the results of the study can be widely applied.

Eligibility criteria:
inclusion criteria: 1. over 40 years old 2. acute ischemic attack 3. symptoms occurred within 24 hours after randomization exclusion criteria: 1. dual antiplatelet therapy with asa and p2y12 inhibitors is needed 2. antiplatelet agents other than asa 3. anticoagulant therapy 4. have any atrial fibrillation / flutter 5. renal failure requiring dialysis 6. during pregnancy or lactation
clinical trial of molecular biomarkers in women with uterine cervix cancer

Conditions: Uterine Cervix Cancer

Summary: this is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. women receive standard-of-care radiochemotherapy followed by brachytherapy. blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus dna, and circulating tumor cells.


Eligibility criteria:
inclusion criteria: - untreated pathologically or cytologically-confirmed diagnosis of stage ib3 (\> 4cm), ii, iii, or iva (figo 2018) squamous, adenosquamous, or adenocarcinoma of the uterine cervix not amenable to curative surgery alone. exclusion criteria: * presence of another concurrent active invasive malignancy * prior invasive malignancy diagnosed within the last three years except for \[1\] non-melanoma skin cancer or \[2\] prior in situ carcinoma of the cervix * prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician.
comparison of isometric and isotonic strengthening exercises in chronic neck pain patients.

Conditions: Neck Pain

Summary: study will be a randomized clinical trial to check the effects of isometric and isotonic strength training exercises on patients with chronic neck pain. the data will be collected in a hospital setting where patients of chronic mechanical neck pain will be screened out for the fulfillment of eligibility criteria of this study. after being eligible for this study their baseline outcome measures will be measured using numeric pain rating scale, neck disability index, goniometer, dynamometer and short form 36 survey. then they will be divided into two groups namely group a receiving isometric exercises with conventional treatment and group b receiving isotonic exercises with conventional treatment. here conventional treatment includes thermotherapy, manual mobilisation of cervical and thoracic and trigger point therapy which will be a common treatment for both groups. the outcome measures will be measured later at 4th,8th and 12th week.

chronic neck pain is a burden to health globally and is the major reason behind years of disability. this is due to the higher prevalence, persistence and recurrence.it is a frequent reason for visit to physical therapist or a physician. it is the major health concern for society these days with highest recurrence rate combined with its chronicity. the overall worldwide prevalence for it is 16.7% to 75.1%. there is scarce knowledge of use of isotonic neck muscles strengthening in clinical trials. moreover the literature has not satisfied the long term effects of isometric and isotonic strength training exercises of cervical muscles on improving the health related quality of life and restoring the normal function of cervical spine. the findings of current study will help to establish long term effects of isometric and isotonic strengthening exercises on pain, strength, function and quality of life in chronic mechanical neck pain patients. neck strength training exercises have shown to reduce neck muscle injuries in sports.neck strength training has also proved beneficial in reducing neck pain as part of training. the static muscle contractions of neck muscles of patient being seated with the resistance of palm of physiotherapist being standing will be performed in six cervical movements i.e. flexion, extension, right lateralflexion, left lateral flexion, right rotation, left rotation. the dynamic muscle contractions of neck muscles will be performed using thera-band for resistance tied on the wall for all six movements of cervical spine.

Eligibility criteria:
inclusion criteria: * no discrimination against gender * age group 25-55 years * complain of chronic mechanical neck pain for more than 3 months exclusion criteria: * spinal cord injury * malignancy * cervical fracture * any bony or soft tissue systemic disease * ankylosis spondylitis * craniovertebral disorders * any cervical deformity
drug induced submental ultrasound in obstructive sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: in this study, submental ultrasound during awake and simultaneous under drug-induced sleep endoscopy is applied in the diagnostic workup of obstructive sleep apnea patients. the aim is to assess the tongue base thickness during awake and sleep with different head positions. by correlation with drug-induced sleep endoscopy findings, more parameters could be used for evaluation and management of upper airway collapse in obstructive sleep apnea patients.

obstructive sleep apnea (osa) is a syndrome characterized by recurrent episodes of apnea and hypopnea during sleep that are caused by repetitive upper airway (ua) collapse and often result in decreased blood oxygen levels and arousal from sleep. successful treatment lies in precise mapping the site of airway narrowing. drug-induced sleep endoscopy (dise) is a well described modality to mimic the dynamic change of ua in osa patients during natural sleep. nevertheless, the tongue base thickness (tbt), one of the important anatomic factors in osa, is hard to evaluate under this method. recently, submental ultrasound (us), the noninvasive and convenient tool, has been widely applied to measure the tbt in awake osa patients, so as to predict the severity and relationship with ua collapse. however, few evidence has addressed the relationship between ua collapse and the tbt in different head positions, awake and sleep period in this study, submental us during awake and drug induced sleep period is applied in the diagnostic workup of osa patients. by correlation with dise findings, more parameters could be used for evaluation and management of upper airway collapse in osa patients. key words: submental ultrasound, obstructive sleep apnea, drug-induced sleep endoscopy

Eligibility criteria:
inclusion criteria: * obstructive sleep apnea patients, age between 20-70 exclusion criteria: * severe heart, lung, liver, and kidney comorbidity propofol or dexmedetomidine allergies (albeit rare)

Keywords: submental ultrasound, obstructive sleep apnea
protease activated receptor-2 and gastrointestinal dysfunction in critical illness

Conditions: Gastroparesis; Gastrointestinal Disorder, Functional; Critical Illness

Summary: gastrointestinal (gi) dysfunction affects up to 50% of medical and surgical critically ill children. gi dysfunction, specifically gastric dysmotility and loss of epithelial barrier integrity, is associated with significant morbidity in critical illness. the mechanisms underlying gi dysfunction in critical illness are not well understood. gi dysfunction in surgery and critical illness has been associated with inflammation. there is evidence to suggest the protease-activated receptor 2 (par2) is a link between inflammation and gi dysfunction. par2 is a g-coupled receptor present throughout the gi tract. par2 mediates gi motility and epithelial barrier integrity. par2 is activated by par2 agonists, specifically gi serine proteases and zonulin, released under conditions of inflammation. in this study the investigators will examine the relationship between inflammation and par2 activation by par2 agonists and subsequent gi dysfunction in pediatric critically ill surgical patients. the overall hypothesis of this study is that par2 activation by par2 agonists, gi serine proteases and zonulin, released due to inflammation results in gastric dysmotility and loss of epithelial barrier integrity. in this study, the investigators will examine whether par2 agonist expression is increased and correlates with gi dysfunction in critically ill surgical pediatric patients. this proposal fills a knowledge gap in the understanding of mechanisms for gi dysfunction in critical illness, and will be applicable to all surgical and medical critically ill children.

the investigators in this study aim to examine a plausible mechanism by which gastrointestinal dysfunction, gastric dysmotility and loss of epithelial barrier integrity, occur in critical illness. specifically, the investigators will examine whether an increase in par2 agonist levels, zonulin and serine proteases, are associated with gastric dysmotility and loss of epithelial barrier integrity in critical surgical illness in children. the investigators will examine gi function, gastric motility and epithelial barrier integrity, and par2 agonist levels, zonulin and serine protease, in participants before surgery and after surgery. specifically, children undergoing posterior spinal fusion, a known significant inflammatory trigger, and with planned admissions to the intensive care unit will be enrolled. gastrointestinal function and par2 agonist levels will be tested non-invasively in blood and stool.

Eligibility criteria:
inclusion criteria: * 2 years and older exclusion criteria: * liver dysfunction * renal dysfunction * pre-diagnosed gastroparesis/ delayed gastric emptying * pre-diagnosed gastrointestinal malabsorption * contraindication to acetaminophen administration

Keywords: pediatric critical illness surgery gastrointestinal dysfunction gastric emptying epithelial barrier nutrition
ciclosporin in the management of steroid resistant type 1 reactions in leprosy

Conditions: Leprosy

Summary: study 1b: ciclosporin in the management of steroid resistant type 1 reactions in leprosy objective: a pilot study assessing the efficacy and safety of ciclosporin as a second -line drug in patients with type 1 reactions who have not responded to a 12 week course of prednisolone.


Eligibility criteria:
inclusion criteria: * individuals with clinical evidence of type 1 reaction who have not responded to 3 months prednisolone treatment * aged 18-65 * weigh more than 30kg exclusion criteria: * unwillingness to give informed consent * patients with severe active infections such as tuberculosis * pregnant or breastfeeding women (see appendix ii) * those with renal failure, abnormal renal function, hypertensive * patients taking thalidomide currently or within the last 3 months * patients not willing to return for follow-up * women of reproductive age not willing to use contraception for the duration of the study ( see appendix ii) * hiv positive

Keywords: leprosy type 1 reaction prednisolone ciclosporin